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Abstract
Background: The assessment of airway inflammation for the diagnosis of asthma or COPD is still
uncommon in pneumology-specialized general practices. In this respect, the measurement of exhaled nitric
oxide (NO), as a fast and simple methodology, is increasingly used. The indirect assessment of airway
inflammation, however, does have its limits and therefore there will always be a need for methods enabling
a direct evaluation of airway inflammatory cell composition. Sampling of spontaneous sputum is a well-
known, simple, economic and non-invasive method to derive a qualitative cytology of airway cells and here
we aimed to assess today's value of spontaneous sputum cytology in clinical practice.
Methods: Three pneumologists provided final diagnoses in 481 patients having sputum cytology and we
retrospectively determined posterior versus prior probabilities of inflammatory airway disorders.
Moreover, in a prospective part comprising 108 patients, pneumologists rated their confidence in a given
diagnosis before and after knowing sputum cytology and rated its impact on the diagnostic process on an
analogue scale.
Results:  Among the 481 patients, 45% were diagnosed as having asthma and/or airway
hyperresponsiveness. If patients showed sputum eosinophilia, the prevalence of this diagnosis was elevated
to 73% (n = 109, p < 0.001). The diagnosis of COPD increased from 40 to 66% in patients with neutrophilia
(n = 29, p < 0.01).
Thirty-three of the 108 patients were excluded from the prospective part (26 insufficient samples, 7
incomplete questionnaires). In 48/75 cases the confidence into a diagnosis was raised after knowing
sputum cytology, and in 15/75 cases the diagnosis was changed as cytology provided new clues.
Conclusion: Our data suggest that spontaneous sputum cytology is capable of assisting in the diagnosis
of inflammatory airway diseases in the outpatient setting. Despite the limitations by the semiquantitative
assessment and lower sputum quality, the supportive power and the low economic effort needed can
justify the use of this method, particularly if the diagnosis in question is thought to have an allergic
background.
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Background
Airway inflammation is a hallmark of asthma [1] and
chronic obstructive pulmonary disease (COPD) [2], and
there is evidence that the assessment of inflammation is
useful for diagnosis [3-5]. In addition, monitoring inflam-
mation by induced sputum analysis or the measurement
of exhaled nitric oxide (NO), led to a lower frequency of
exacerbations in asthma [6,7], and allowed to reduce the
dose of inhaled corticosteroids [8].
The induction and processing of sputum for a quantitative
differential cell count is, however, very labour-intensive,
time-consuming and therefore not suited to be performed
in outpatient clinics. The analysis of NO is fast and simple
and offers many of the ideal features a tool to assess
asthma control should provide [9]. However, it requires
the investment for an NO-analyser and, more impor-
tantly, provides only indirect evidence for eosinophilic
airway inflammation, which can be difficult to interpret,
when e.g. high NO values persist, despite increases in ster-
oid dose [10]. In these cases, an additional direct assess-
ment of the type of airway inflammation could be helpful.
The use of spontaneous sputum, on the other hand, is
simple, as samples can be produced by the patients at
home. Although today not routinely used, it has a long
history as a tool in pneumology. It does not require
investments for equipment and cytological analysis of
smear slide preparations are generally reimbursed by
health insurances (e.g. in Germany). However, samples
are often of lower quality than induced sputum, partly
due to the unsupervised production and the delayed anal-
ysis of mailed samples. In addition, smear slides samples
provide only semiquantitative information. Despite these
obstacles, it seems worthwhile to assess the diagnostic
value of this economic methodology in pneumological
practices.
We thus analysed the relationship between final diagnosis
and cytological result for spontaneous sputum samples of
481 patients provided by pneumology-specialised general
practitioners. In this retrospective part, we calculated the
prior probability for different airway diseases as well as
their posterior probabilities for patients with pronounced
eosinophilic or neutrophilic inflammation. This
approach provided the information that was used to esti-
mate the diagnostic value of spontaneous sputum analy-
sis. In a prospective part including 108 newly recruited
patients without known diagnosis, three pneumologists
were asked to rate their confidence in a specific diagnosis
asserted before and after cytology, as well as the subjective
importance of the cytological result for the respective
diagnostic process.
Methods
Patients and pneumology-specialized general practitioners
The co-operating pneumology-specialized general practi-
tioners of the Hamburg/Kiel area covered internal medi-
cine with focus on pneumology. Each sputum sample was
mailed to the cytologist and accompanied by information
on the suspected indication (inflammatory disorder, sus-
pected tumour, hemoptysis, dust exposure, unknown).
Irrespective of this, the cytologist (L.W.) always put atten-
tion to all these aspects. Samples as well as patients' char-
acteristics were coded and all other participating
researchers were blinded with the respect to the identity of
the patient.
Spontaneous sputum samples
Patients received a 50 mL tube and a labelled envelope.
They were instructed how to produce sputum in the
morning at home and to immediately send the tube to the
Cytological Laboratory of the Hospital Großhansdorf,
where smear slides were prepared and stained by Giemsa
within one day. The time delay between sputum produc-
tion and processing ranged between 24 and 48 h. Slides
were first rated for quality (sufficient, limited, not suited)
and whether sufficient airway cell numbers were present.
Slides were then scored semiquantitatively, as showing
high, medium, or low numbers of inflammatory cells,
with emphasis on eosinophils and neutrophils. The terms
eosinophilia and neutrophilia refer to slides with high
counts of these cells. In addition, the presence of tumour
cells or other suspicious alterations was recorded. The
pneumologist was informed about the result within one
day after analysis.
Retrospective part
Data from samples collected over a 2-year period were
included. To reduce the variability arising from differ-
ences between the pneumologists' habits, only the three
physicians with the largest numbers of patients were
included. Final diagnoses were extracted from 481 patient
files of these physicians. The diagnosis of asthma and
COPD was based on international guidelines [1,2]. To
accommodate for remaining differences in terminology,
final diagnoses were grouped into seven major categories:
(1) healthy, (2) asthma and/or bronchial hyperrespon-
siveness (BHR), (3) COPD/bronchitis, (4) pneumonia,
(5) alveolar haemorrhage, (6) tumour, (7) others. Fre-
quencies according to the final diagnosis were taken as
prior probabilities for each diagnostic group. Sputum
samples were categorised into the same groups, taking
into account the whole pattern of alterations. Especially
eosinophils and neutrophils allowed to state cytological
diagnoses for groups (2) and (3). The comparison
between final diagnosis and the specific cytological find-
ings or the cytological diagnostic category then allowed to
compute posterior probabilities. This type of analysis wasBMC Pulmonary Medicine 2008, 8:5 http://www.biomedcentral.com/1471-2466/8/5
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restricted to groups (2) and (3), as these comprised the
majority of cases. The change from prior to posterior
probability was taken as a measure of the predictive value
of sputum analysis. We preferred to analyse the data this
way, as it takes into account disease prevalence which is
important under practical aspects.
Prospective part
The same three pneumologists, blinded to the results of
the retrospective analysis, were asked to include patients
in whom the diagnosis of airway disease had not yet been
established. Samples were collected over a 6-month
period. Patients underwent the diagnostic procedures
commonly used in the respective outpatient clinic. The
pneumologists were then asked to rate their confidence in
the diagnosis without knowing sputum cytology (Rating
1). Within 5 days after having received the cytological
result, the pneumologists then repeated the rating (Rating
2). Each rating was performed on a separate analogue
scale for each of the 7 diagnostic groups asthma, COPD,
infection/pneumonia, BHR, tuberculosis, reflux, tumour.
Scales were labelled "unsure" (0 mm) and "sure" (100
mm) and the rating was quantified in mm. The results of
the repeated ratings were compared (changes from Rating
1 to Rating 2) and grouped into four classes: (C) increase
in distance = diagnosis confirmed by sputum and confi-
dence in the diagnosis increased, (N) change in diagnostic
group = sputum providing new clues for diagnosis, (U)
distance unchanged = no information, (L) reduction in
distance = sputum rendering diagnosis less likely but not
providing new clues.
In addition the pneumologists were asked to answer the
following questions on analogue scales (Rating 3)
labelled "do not agree" (0 mm) and "agree" (100 mm):
knowledge of sputum cytology either confirmed the diag-
nosis, or had an impact on treatment, or enabled a faster
final diagnosis, or had saved costs, or resulted in a more
successful treatment, or provided new diagnostic and/or
therapeutic clues.
Statistical analysis
Prior and posterior probabilities were compared with
each other by the χ2-statistics. Median values and quartiles
of distances on analogue scales (mm) were calculated. The
Wilcoxon matched-pairs signed-ranks test was used for
the analysis of changes of analogue scales. Statistical sig-
nificance was assumed for p < 0.05.
Results
Retrospective part
Within 2 years 1434 samples from 1147 patients were
sent to the Cytological Laboratory by 25 pneumology-spe-
cialized general practitioners. In 63% of cases the indica-
tion to ask for sputum analysis was a suspected
inflammatory disorder, followed by 18% with suspected
tumour, 8% with suspected haemoptysis, and 11% with-
out specified indication. Samples were of sufficient qual-
ity in 78% of patients and of limited quality in 22%,
mainly due to the presence of large proportions of saliva.
In the subgroup of 481 patients with known final diagno-
sis the pneumologists suspected an inflammatory disor-
der in 79% of cases, followed by 8% with suspected
tumour. Sputum quality in this subset was similar to that
of the total group (77% sufficient, 23% limited). In case
of repeated determinations the first adequate sample of a
patient was used for the analysis.
Table 1 lists the relative frequencies of diagnoses for all
sputum samples (prior probabilities), as well as for the
subgroups showing high eosinophil counts and high neu-
trophil counts (posterior probabilities). If there was
marked eosinophilia irrespective of neutrophil counts (n
= 109), the probability of the asthma/BHR final diagnosis
was raised from 45 to 73% (χ2: p < 0.0001). Conversely,
if neutrophilia was pronounced (n = 29), that of COPD/
bronchitis was increased from 40 to 66 % (χ2: p = 0.008).
Table 1: Results of retrospective analysis of spontaneous sputum samples
Prior Probability (in %) Posterior probability after sputum analysis (in %)
Final diagnosis n Eosinophilia Neutrophilia
Healthy 3 0.6 0.0 0.0
Asthma/BHR 216 44.9 72.5 13.8
COPD/bronchitis 194 40.3 22.9 65.5
Pneumonia 16 3.3 0.0 13.8
Alveolar haemorrhage 4 0.8 0.0 0.0
Tumour suspicious 19 4.0 2.8 6.9
Others 29 6.0 1.8 0.0
Total 481 100 100 100
n corresponding to column 481 109 29
The table presents the percentages of patients according to final diagnosis (prior probabilities) as well as posterior probabilities according to the 
two major outcomes (eosinophilia and neutrophilia) of the semiquantitative sputum analysis. Only these two diagnostic categorie are shown, as 
numbers regarding other sputum findings were too low for statistical analysis.BMC Pulmonary Medicine 2008, 8:5 http://www.biomedcentral.com/1471-2466/8/5
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Three patients showed a final diagnosis of bronchitis/
COPD and both marked eosinophilia and marked neu-
trophilia. A neutrophilic response can also be expected in
pneumonia. Despite a low a priori probability (3%) we
also observed a significant increase to 13% in samples
with high neutrophil counts (χ2: p = 0.05). When consid-
ering the 369 sputum samples of sufficient quality only,
similar results were obtained (p = 0.002, 0.001 and 0.01,
respectively). When considering only those patients,
whose sputum was submitted to evaluate a potential
inflammatory disorder (n = 382), results were similar (p =
0.007, 0.006 and 0.03, respectively).
In some of the 481 samples, other cytological aspects such
as the degree of degranulation, number of siderophages,
Charcot-Leiden crystals or pigment within cells were
noted. The frequency of these features was too low for
quantitative analysis, although they might have had an
impact in individual samples.
Prospective part
A total of 108 patients were included into this analysis, of
whom 26 (24%) did not produce adequate sputum sam-
ples. These patients as well as further 7 patients with
incomplete questionnaire data were omitted. The remain-
ing 75 patients were categorised according to the diagnos-
tic scores and questionnaire data provided by the
pneumologists (Figure 1, Table 2).
Within category "C" (suspected diagnosis confirmed,
more confident) sputum eosinophilia played the major
role (30/48 cases). Correspondingly, the "confirmed"-rat-
ing for asthma and/or BHR (n = 29) and/or rhinitis (n =
1) increased from 71(50;87) to 91(75;95) mm (median
(quartiles)) (Wilcoxon: p < 0.001). In 9 patients a marked
neutrophilia was considered as confirming the initial
diagnosis of COPD, infection or pneumonia and in one
patient neoplastic changes confirmed the suspected
tumour diagnosis.
Regarding category "N" (new clue), the presence or
absence of eosinophilia was responsible for a change in
the likelihood of the diagnosis in 12 patients. In the
remaining 3 patients non-specific inflammation resulted
in increases for the confidence into a COPD or infection
or pneumonia diagnosis. For both categories "C" and "N",
pneumologists reported that the sputum analysis had
influenced the further treatment of the patient, by giving
a high score in Rating 3 ("impact").
In category "U" the low scores in the questionnaire indi-
cated that the pneumologists did not find sputum cytol-
The impact of spontaneous sputum cytology on the diagnostic process of 108 new patients of 3 pneumology-specialized gen- eral practitioners Figure 1
The impact of spontaneous sputum cytology on the diagnostic process of 108 new patients of 3 pneumology-
specialized general practitioners. Patients underwent the diagnostic procedures commonly used in the respective prac-
tice. The pneumologists then rated their confidence in the diagnosis before knowing sputum cytology and again after having 
received the cytological result. The repeated ratings on analog scales were compared: increase in distance = diagnosis con-
firmed, change in diagnostic group = sputum provided new clues, distance unchanged = no additional information, reduction in 
distance = sputum rendered diagnosis less likely but provided no new clues.BMC Pulmonary Medicine 2008, 8:5 http://www.biomedcentral.com/1471-2466/8/5
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ogy particularly helpful in these instances, either due to an
already well-established diagnosis, or due to inconspicu-
ous findings of weak non-specific inflammation.
In category "L" sputum cytology led to a decrease in the
score of the suspected diagnosis, without providing new
clues, in 5 patients. For both categories "U" and "L", vari-
ability within analogue scales was large, indicating that
the information by sputum cytology was not considered
generally informative.
Discussion
The results of this study indicate that spontaneous sputum
cytology is feasible and can assist in the diagnostic process
in pneumology-specialized general practices. As expected,
spontaneous sputum eosinophilia was associated with an
increased likelihood of asthma or related syndromes.
Although sputum production at home resulted in about
one quarter of inadequate samples, about 80 % of the
remaining cases showed a diagnostic impact as reported
by the pneumologists. Provided that the limitations of the
semiquantitative method are acknowledged, the use of
spontaneous sputum therefore offers pneumology-spe-
cialized general outpatient clinics a simple and economic
way to support the diagnosis of airway diseases by yield-
ing clues on airway inflammation. In this respect, it could
also assist in cases, where exhaled NO measurements do
not provide conclusive data.
The study was designed to assess the usefulness of sponta-
neous sputum under the same conditions as encountered
in daily clinical practice. We thus tried to obtain data
without interfering with the routine procedures followed
by each of the participating pneumologists. Despite
adherence to national and international guidelines, each
practitioner followed a diagnostic process that took the
needs of individual patients as well as the own experience
into account. This also implied that we did not prescribe
the set of allowed diagnoses which, as a consequence,
comprised syndromes such as BHR in addition to asthma.
Even in the prospective part we completely left the pre-
ferred approach of diagnosing and the sequence of meas-
urements to the pneumologists and did not ask to follow
a specific protocol, as commonly used e.g. in multicenter
clinical trials.
The decision on requiring sputum cytology was also left to
the pneumologists. It was based on the patient's clinical
history and the results of standard diagnostic procedures
(patients' history, physical examination, symptoms,
measurement of lung function, reversibility, and hyperre-
sponsiveness). The pneumologists, all of them with spe-
cific experience over ≥10 years, founded their initial
diagnosis on these results. As the prospective part of the
study indicated, the pneumologists already expressed a
high confidence into their initial diagnosis in most
patients and often asked for sputum cytology for confir-
mation. Accordingly, the ratings generally increased after
knowing the sputum result. Taken together with positive
scores in the first three questions of the questionnaire
("confirm", "impact", "faster"), this suggests that sputum
cytology was considered as helpful. In addition, adequate
treatment was felt to be established with more confidence
and in shorter time as compared to cases without sputum
data. This also might explain why sputum analysis has
been used regularly over time by many pneumologists in
our area.
In most instances, in which cytology provided new clues,
the finding of eosinophilia redirected the pneumologist's
attention towards an allergic disease such as asthma.
Although new clues were found in only 10% of all cases,
this seems to be an important observation, demonstrating
that even limited additional information on airway









New clue for 
diagn.
Category according 
to change in analog 
scales of diagnoses
nm m m m m m m m m m m m
Overall 75 80 (52;94) 85 (50;92) 85 (52;95) 50 (45;85) 55 (50;87) 10 (2;50)
C (confirmed, more 
confident)
48 90 (80;100) 90 (65;97) 90 (85;100) 50 (50;90) 80 (50;90) 10 (3;15)
N (new clue) 15 50 (15;60) 80 (65;90) 60 (50;85) 50 (50;60) 60 (50;87) 86 (50;90)
U (unchanged) 7 52 (5;55) 45 (5;50) 50 (5;52) 42 (5;50) 45 (40;50) 25 (5;38)
L (less likely, no new 
clues)
5 75 (15;100) 50 (15;80) 70 (15;100) 15 (12;50) 50 (15;50) 15 (12;50)
Data represent median (quartiles) distances in mm on the analog scales of Rating 3 assessed after sputum analysis, whereby 0 indicates a negative 
and 100 a positive (affirmative) answer. To check the association of these general ratings with the changes in the rating regarding specific diagnoses, 
answers were further grouped (C, N, U, L) according to the comparison between Rating 1 (prior to sputum analysis) and Rating 2 (performed after 
having received the sputum result). The bold face type indicates the scores ≥ 80 in Rating 3.BMC Pulmonary Medicine 2008, 8:5 http://www.biomedcentral.com/1471-2466/8/5
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inflammation as supplied by a semiquantitative method
has the power to alter the opinion of an experienced phy-
sician. At the time of the study, measurements of NO were
not available in clinical practices. It might well be that
many patients with eosinophilia would also have been
detected using NO [3,11]. We do not believe, however,
that this renders spontaneous sputum analysis useless, as
NO is known to provide very limited information in
patients with neutrophilic inflammation, as found in
COPD, current smokers, infections, or pneumonia [3].
We are well aware of the fact that the freedom in choosing
diagnostic procedures introduced additional variability
and potentially also a bias. The information policy in the
prospective part of the study, however, prevented the
pneumologists from using sputum data ahead of time,
and the adherence to usual clinical habits ensured that the
results reflected the situation of clinical practice. The study
was performed in collaboration with pneumologists who
had long experience in the use of spontaneous sputum.
This might have favoured the inclusion of patients in
whom sputum cytology tended to be particularly success-
ful. In fact, the focus was on inflammatory processes, add-
ing up to 79% of all submitted samples.
In the retrospective analysis we observed that the presence
of marked eosinophilia and neutrophilia beared signifi-
cant information, by altering the posterior probability for
asthma/BHR or COPD/bronchitis. Interestingly, there was
a high number of patients with eosinophilia and the final
diagnosis of COPD without asthma. This also occurred in
the prospective part; in the patients in whom eosinophilia
was stated (n = 4) it did, however, not alter the confidence
in the initial diagnosis of either COPD, bronchitis, or
infection. Possibly, patients had eosinophilic bronchitis,
or showed exacerbations of COPD, as characterised by
eosinophilia and an increase in BHR [12]. Being aware
that eosinophilic airway inflammation is responsive to
treatment with corticosteroids, the information of ongo-
ing eosinophilic inflammation is important and able to
assist in the decision on the quality of treatment irrespec-
tive of the diagnostic label of the disease.
The study was based on the experience gained in the anal-
ysis of approximately 5000 sputum samples in the past 10
years. It suggests that an experienced observer can score
degree and type of inflammation in most samples, even
without fixation and with a delay of 1–2 days prior to
processing. Eosinophils are rather resistant to degradation
and were often found with intact cytoplasm and granular
staining. Neutrophils were more often destroyed and
remained in groups. Due to their sensitivity to destruction
and the time delay it might be that neutrophilic inflam-
mation has been underestimated in the samples. There-
fore spontaneous sputum is more likely to display
eosinophilic inflammation and consequently to help
especially in the diagnosis of asthma, allergic airway dis-
eases [13,14], as well as steroid responsive airway dis-
eases. These factors can also be addressed indirectly by the
measurement of exhaled NO, however currently no stud-
ies are available comparing the clinical usefulness and
reliability of these different ways of analysing airway
inflammation.
Conclusion
In summary the results of this study showed that sponta-
neous sputum cytology can be helpful in the diagnosis of
inflammatory airway diseases. Although it provided only
semiquantitative and delayed information, it had the
advantage to be feasible and not to require investments of
time and money. Thus spontaneous sputum analysis
offers a way for pneumologists to assess airway inflamma-
tion within outpatient settings. The same is probably true
for GPs with focus on internal medicine. If NO measure-
ment is available, sputum analysis probably still has the
potential to assist in cases where NO does not lead to use-
ful results. Our observations favour an increased use of
spontaneous sputum analysis, especially in the assess-
ment of suspected diagnoses of allergic background.
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